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Abstract
Background:  Ser-249 TP53 mutation (249Ser) is a molecular evidence for aflatoxin-related
carcinogenesis in Hepatocellular Carcinoma (HCC) and it is frequent in some African and Asian
regions, but it is unusual in Western countries. HBV has been claimed to add a synergic effect on
genesis of this particular mutation with aflatoxin. The aim of this study was to investigate the
frequency of 249Ser mutation in HCC from patients in Brazil.
Methods: We studied 74 HCC formalin fixed paraffin blocks samples of patients whom underwent
surgical resection in Brazil. 249Ser mutation was analyzed by RFLP and DNA sequencing. HBV DNA
presence was determined by Real-Time PCR.
Results: 249Ser mutation was found in 21/74 (28%) samples while HBV DNA was detected in 13/
74 (16%). 249Ser mutation was detected in 21/74 samples by RFLP assay, of which 14 were
confirmed by 249Ser mutant-specific PCR, and 12 by nucleic acid sequencing. All HCC cases with
p53-249ser mutation displayed also wild-type p53 sequences. Poorly differentiated HCC was more
likely to have 249Ser mutation (OR = 2.415, 95% CI = 1.001 – 5.824, p = 0.05). The mean size of
249Ser HCC tumor was 9.4 cm versus 5.5 cm on wild type HCC (p = 0.012). HBV DNA detection
was not related to 249Ser mutation.
Conclusion: Our results indicate that 249Ser mutation is a HCC important factor of carcinogenesis
in Brazil and it is associated to large and poorly differentiated tumors.
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Background
Many factors may lead to pre-malignant conditions
related to the development of hepatocellular carcinoma
(HCC), including Hepatitis B and C virus infection (HBV,
HCV), alcohol intake and ingestion of food product with
high concentration of mycotoxins such as Aflatoxin B1
(AFB1), which can be found in some developing countries
[1]. Several of these factors have been shown capable of
altering the expression of genes responsible for cell
growth regulation [2,3].
It has been widely acknowledged that HCC development
is strongly related to environment and socio-economic
factors [4], leading to major differences not only in the
incidence but also in molecular pathways of liver carcino-
genesis in different geographic regions. Accordingly,
mutations at TP53 gene are frequent in HCC patients from
Africa and China, where this kind of tumor is highly inci-
dent, in sharp contrast to what has been reported from
Europe and North America [5]. Further evidences for a
direct carcinogenic effect of HBV and AFB1 is the finding
which in countries where high rates of both ones are
present and, furthermore, HBV infection is contracted in
the early years of life, a higher frequency of HCC in non-
cirrhotic liver is observed. On the other hand, in devel-
oped countries, HCC seems to be more related to HCV
infection and to ethanol intake[6,7,5].
Rather than occurring at random, mutations along TP53
in HCC happen in "hot-spots", the most common of
them is at codon 249 in exon 7, responsible for almost
40% of TP53 mutations reported in this neoplasm (IARC,
2004). It is referred as 249Ser, because of a conversion of G
(guanine) into T (thymine) resulting in Arginine → Serine
mutation in p53 protein. This event was first reported in
1991 simultaneously by two different research groups
[8,9], independently demonstrating a strong relation of
this mutation to a dietary exposure of AFB1. Latter it was
described the geographical distribution of this specific
mutation and its relation to AFB1 exposure [10].
Evidence from several other laboratories has further con-
firmed the strict relation between AFB1 and 249Ser muta-
tion of TP53: Jackson and co-workers [11] found this
mutation in the serum of 46.7% HCC patients in Qidong
(China). In a similar study from Gambia[12], this muta-
tion was found in 36% of HCC patients sera, in 15% cir-
rhotic patients and in 6% of the control group.
Although the pathway on which aflatoxin induces this
specific mutation, it is not totally elucidated, it is known
that AFB1 itself is not the carcinogenic substance, but its
second metabolite [13]. After being ingested along with
the food, AFB1 is metabolized by CYP450 complex
enzymes resulting on formation of AFB1-exo-8,9-epoxide.
This specific metabolite has the capacity to make a cova-
lent binding to DNA nucleotides leading adducts, the
main of which resulting from the interaction between the
epoxide and guanine: AFB1-N7-Gua [14]. It has been
demonstrated that AFB1 can interact with 20% of the
bases between exon 5 and exon 8 of TP53 – 85% of them
were guanines [15]. Besides this hot-spot, Denissenko
[16] detected adducts formation in other codons of exon
7 and 8 of TP53.
Studies indicate that the main risk for the adducts forma-
tion is the incapacity of metabolism phase 2 enzymes,
especially isoforms of Glutatione S-Transferase on clear-
ing AFB1-exo-8,9-epoxide [17].
The carcinogenic process derived from HBV infection has
been associated to the expression of HBx oncoprotein
[18]. Kim et al [19] in 1991, had already shown the role
of HBx in neoplastic transformation in transgenic mice
and the expression of this viral oncoprotein has been
observed in more than half of HBV related HCC [20].
Relationship between HBV infection and p53 function is
still controversial. Hosono and co-workers [21] did not
find any association. Recently it was concluded that HBV
transfection may lead to an abnormal expression of p53 in
cell culture [22]. Studies with patient exposed to AFB1 and
infected with HBV suggest a toxin-virus interaction where
HBV is responsible to selectivity of 249Ser mutation [23].
The aim of this study was to assess the frequency of TP53
249Ser mutation in HCC samples from patients in Brazil as
well as its eventual relation to the presence of HBV DNA
in hepatocytes by Real-Time PCR.
Methods
Patients
Formalin fixed paraffin embedded (FFPE) blocks diag-
nosed as HCC from 80 patients from Division of Surgical
Pathology at the Hospital das Clínicas of University of São
Paulo School of Medicine (51 samples) and from
Oswaldo Cruz German Hospital (29 samples) were
selected from patients who underwent liver resection or
liver transplantation from 1998 to 2005. Six patients were
excluded because DNA was not amplified by PCR, there-
fore analysis included 74 patients. The characteristics of
patients are described in table 1.
Additionally, 17 FFPE blocks of normal livers from
patients who died from unrelated diseases necropsied at
the Department of Pathology of University of São Paulo
School of Medicine served as control group.
This study was approved by the Investigational Review
Board of the University of Sao Paulo School of Medicine.BMC Cancer 2009, 9:204 http://www.biomedcentral.com/1471-2407/9/204
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DNA extraction
In order to avoid inter sample contamination, it was used
a different sterile blade for each paraffin block. Samples
were macro dissected, selecting the most preserved areas
of HCC. The area of interest was cut at 10 micra thick
slices, which were deparaffinized using Xylene and Etha-
nol. Paraffin free samples were digested with a 20 mg/ml
Proteinase K solution and lysis buffer. DNA was extracted
by DNeasy® Tissue Mini-Kit (Qiagen, Hilden, Germany),
according to the manufacturer's instructions and eluted in
150 μl of Elution Buffer. The concentration and the integ-
rity of the DNA were analyzed by 1.5% agarose gel electro-
phoresis, using Low Mass DNA Ladder (Invitrogen,
Carlsbad, California) as marker.
DNA Amplification
The selected primers for this study flank TP53 exon 7 and
were designed according to Lehman [24] in order to
amplify the whole sequence of the target exon. Five μl of
the eluted DNA was used as template for the PCR at a final
concentration of 100 nM of each primer (forward and
reverse); 0.1 mM of each dNTP; 1.5 mM of MgCl2; 1× reac-
tion Buffer and MilliQ water completing the reaction to a
final volume of 50 μl. No-template-controls were used for
each PCR set to check for contamination.
PCR products were quantified using Low Mass Ladder
(Invitrogen Carlsbad, California).
For DNA amplification with mutant specific primer, an
additional reverse primer (5'tgt gat gat ggt gag gat ggg a 3')
was added to the PCR reaction described above. A wild
type TP 53 control was used as negative control for TP-53
mutation.
Mutation Analysis
Restriction Fragment Length Polymorphism (RFLP)
Specific G to T transversion at codon 249 of exon 7 of
TP53 was analyzed through RFLP. One unit of HaeIII (a
10 fold excess of enzyme) was added in 100 ng of p53
PCR product with its specific reaction buffer. The reaction
was incubated at 37°C for 4 hours. Afterwards, an electro-
phoresis of the restricted PCR product in a 3% agarose
1,000 gel (Invitrogen, Carlsbad, USA) was performed. A
158 bp DNA fragment denoted the specific mutation.
Sequencing
In order to validate the results from RFLP, exon 7 region
of the TP53 gene was directly sequenced. 30 ng of PCR
product was used as template for sequencing reaction; 3.2
picomols of primer and 6 μl of Big Dye Terminator
(Applied Biosystems, Foster City, USA), the reaction vol-
ume was completed with MilliQ water to a final volume
of 20 μl. It was used ABI 377 automated sequencer
(AppliedBiosystem, Foster City, USA).
Assessment of the presence of HBV DNA in liver tissue
A qualitative assay using Real-Time PCR was performed to
detect HBV DNA in the eluted total DNA from the hepatic
tissue from all cases and controls, with primers and
probes from the Protein S region of the HBV genome.
Both primers and probes were designed to cover all A, B,
C, D, E and F HBV genotypes (primers have not been pub-
lished yet). Briefly 5 μl of the DNA solution was used as
template along with 1× TaqMan mastermix (Roche), 100
nM of each primer and 50 nM of a 5'FAN 3'MGB probe. It
was used the 7300 Real-Time thermocycler (Applied Bio-
systems, Foster City, USA).
Statistical analysis
Univariate statistical analysis was performed using x2 test
and Student's t-test. Upon completion of the univariate
analyses, variables were select for the multivariable analy-
sis. Any variable whose univariate test had a p-value <
0.25 was considered as a candidate for multivariate model
along with all variables of known biologic importance.
The 0.25 level was chosen as a screening criterion because
studies have shown that using a lower level (e.g. the tradi-
tional 0.05 level) often fails to identify variables known to
be important. And the populated multivariate model will
control for bias and exclude those with the p level of 0.05.
Therefore following the above criteria the following varia-
bles were chosen for multivariate analysis: age, sex, ethnic
origin, presence of cirrhosis, tumor differentiation grade,
tumor size, vascular invasion and HBV positivity by Real
Time PCR. The multivariate logistic regression used a for-
Table 1: Patients Characteristics
Characteristic Number (%)
Gender
Male 53 71.6
Female 21 28.4
Age, years 54.04 ± 17,31 7 – 802
Viral etiology
HBV 13 16
HCV 27 48.23
HBV + HCV 3 5.43
No virological data 12 21.4
Cirrhosis 49 66.2
Tumor size 6.58 + 5.91 0.5 – 242
Tumor differentiation grade
G1 1 1.4
G2 30 40.5
G3 34 45.9
G4 9 12.2
Geographical area
North 1 2.3
Northeast 6 13.9
Southeast 35 81.3
Outside Brazil 1 2.3
1Mean ± SD; 2Range; 3 Sample size: 56BMC Cancer 2009, 9:204 http://www.biomedcentral.com/1471-2407/9/204
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ward selection procedure and only those variables with
significant p at 0.05 were included in the final model. All
p values reported are for a two-sided test, and the level of
significance was set at 0.05.
Results
Pathological data
From the 74 FFPE blocks in which yielded DNA amplifi-
cation, 49 (66.2%) presented liver cirrhosis. The mean
tumor size was 9.08 cm (0.5 – 24 cm). Grossly the tumor
showed vascular invasion in (45.9%) of the samples.
Tumor grade was classified according to the Edmond-
Steiner criteria, in which G1 is a well-differentiated tumor
and G4 is the most undifferentiated form. Of all samples
1/74 (1.35%) case was classified G1, 30/74 (40.5%) G2,
34/74 (45.9%) G3 and 9/74 (12.2%) G4.
Clinical Data
Fifty-three were male patients (71.6%) and the average
was 54.04 years. The HCV infection data was obtained
from Clinical Hospital of Sao Paulo University School of
Medicine electronic system and from CICAP – German
Hospital Oswaldo Cruz in 56 patients whereas HBV DNA
by Real-Time PCR was achieved in all 74 patients. The
resulting "viral status" showed that 27/56(48.2%) were
HCV infected, 13/74 (17.6%) HBV infected, 3/56 (5.4%)
co-infected and 12/56(21.4%) with no viral infection.
DNA Extraction and PCR Amplification
DNA extraction was performed as described above. The
mean DNA concentration extracted was 40 ng/ml. Even
though the extraction was successfully done in all sam-
ples, 6 of them was not observed PCR amplification and
were excluded from the study. The absence of amplifica-
tion in those samples may be due to an excessive degrada-
tion of the genomic DNA.
Mutation and HBV DNA Presence
249Ser mutation was found in 21/74 samples (28%) by
RFLP and all samples were also submitted to sequencing
(Figure 1). The presence of mutation was confirmed in 12
of 21 samples by nucleic acid sequencing (Figure 1). No
mutation was detected in any of the 17 controls. To fur-
ther demonstrate the presence of the TP-53 mutant form,
an alternative PCR amplification with a reverse TP-53
mutant-specific primer was performed in 14 of the 21
samples available for PCR. A 155 band confirmed the
presence of the mutant form. A wild type TP 53 DNA
(Lane 15) was used as a wild form control (Figure 2). In
all 14 samples, the intensity of mutant p53-specific band
was lower than that of wild-type p53, suggesting that all
tumors retained wild-type p53 or alternatively a fraction
of tumor cells displayed the p53-249ser mutation.
The assessment of sensibility of Real-Time qualitative
assay was done by a serial dilution of pSM2 – a plasmid
containing the whole genome of HBV described by
Günther [25]. The minimum amount of HBV DNA neces-
sary for detection was 5 copies per reaction.
Using the same parameters from the standardization, it
was observed HBV DNA amplification in 13/74 (16%)
samples
Variables related to 249Ser
The mutation frequency according to HCC differentiation
level is described in table 2. G4 tumors had a tendency to
have higher frequency of 249Ser when compared to the
other levels (p = 0.054, NS).
Tumor size data was available for 68 samples. Mean
tumor samples size presenting 249Ser was 9.4 cm, signifi-
cantly larger (p = 0.015) than that found in cases without
this mutation, which was 5.5 cm as described on table 3.
As it can be seen on table 4, histological grade, and tumor
size increases the odds of presenting 249Ser: OR =
2.415(1.001 – 5.824) and 1.10 (1.001 – 1.214) respec-
tively. Male gender had a borderline result of OR = 4.9173
(0.954 – 25.345).
Mean patient age with or without 249Ser was not signifi-
cantly different (53.05 ± 12.35 years versus 54.41 ± 18.98
years, p = 0.3825). Mutation frequency tended to be
higher in HCC from cirrhotic liver (34.7%) than non-cir-
rhotic (16%). However this difference was not significant
(p = 0.076, NS). Mutation frequency was 3/21 (14.28%)
in female and 18/53 (33.9%) in male (p = 0.076, NS).
HBV presence had a 1.150 (0.312 – 4.237) OR (p =
0.53768) suggesting no relationship between HBV DNA
presence and 249Ser. Neither 249Ser nor HBV DNA pres-
ences were related to vascular invasion (p = 0.470): OR =
0.84 (0.303 – 2.326) and p = 0.611 OR = 1.010 (0.303 –
3.357).
No additional mutation was detected in any other hotspot
of TP53 exon 7 codon 249.
Discussion
The 249Ser mutation was found in 28% of HCC samples
included in this study, it is lower somewhat similar to our
previous finding of immunohistochemistry reactivity for
p53 in 35% of Brazilian HCC cases from our group [26].
At that time only immunoexpression of this protein was
analyzed, not the determination of the mutation at the
hotspot(s) responsible for this over expression.BMC Cancer 2009, 9:204 http://www.biomedcentral.com/1471-2407/9/204
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The 28% rate of 249Ser TP53 point mutation found is
rather high, a finding probably related to previous studies
of contamination of Brazilian food with aflatoxin [27,1].
AFB1 contamination is a public health problem in Brazil.
It is also important to remind that codon 249 is the
responsible for 33% of TP53 mutations in HCC, but it is
not the only TP53 hotspot. In a search on IARC database,
it is possible to find other TP53 hotspots. It is described
other 143 mutations besides 249Ser in HCC. Other com-
mon mutation takes place in codons 175, 245, 248 273,
and 282. The other codons have an individual contribu-
tion to TP53 mutation of less than 2% [28]. This informa-
tion can justify the difference between the frequency of
the mutation found in this study and the higher frequency
of over expressed p53 described previously [26].
Our results are strikingly differing to those published in
European countries where, not only 249Ser, but also all
TP53 hotspots do not have relevant influence in HCC car-
cinogenesis. Kubicka [29] showed that none of his 20
HCC samples had the 249Ser point mutation and between
all cases only one had p53 over expression due to a 248
codon mutation. USA had a similar result: even though
there was 5/23 cases of HCC with p53 over expression all
of them were wild type for the 249 codon [30].
A. RFLPs of PCR-amplified fragments obtained with HaeIII Figure 1
A. RFLPs of PCR-amplified fragments obtained with HaeIII. There are 2 genotypes represented by the gel picture, wild 
type (a, c and d) where a 158 bp band is absent and 249Ser (b, e and f) where the 158 pb fragment can be observed. 1B. Repre-
sentative eletropherograms of TP53 sequence. Nucleotide sequence of a mutated sample on top, showing the G → T transver-
sion (AGT) when compared with a wild type exon 7 below (AGG).
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It was described a 45% frequency of p53 over expression
on his samples – a high rate for Europeans samples – even
though no codon 249 mutation was found [31].
On the other hand, in countries with high incidence of
HCC, the 249Ser point mutation has an important role in
the liver carcinogenesis. In Senegal this kind of mutation
can be detected in 67% of HCC patient [32]. In regions
like Gambia (Africa) and Qidong (China) this mutation
frequency can reach up to 50%. The mutation rate found
in our study is much higher comparing to European coun-
tries yet lower than in regions where aflatoxin exposure is
endemic. Unfortunately, there are not many studies about
249Ser frequency in Latin-American countries. However, in
Mexico it was described a 3/16 (19%) frequency of this
mutation in HCC [33]. This 249Ser frequency may be
related to the fact that Mexico is one of the biggest corn
consumers in the world (almost 120 kg per capita per
year). This fact associated with an imperfect foodstuff stor-
age conditions and manipulation may result in a large
AFB1 intake. Another fact which should be discussed is
the fact that up to 2005, Mexican legislation about Afla-
toxin contamination lack of rules about Aflatoxin pres-
ence in milk [34].
Although, AFB1 contamination has been controlled in
Brazil, there are still cases of foods presenting AFB1 levels
beyond the tolerated level, for example: 20 kinds of pea-
nuts were interdicted during February 2005 and July 2006
by ANVISA (National Sanitary Administration Agency)
[35]. The maximum AFB1 level in food allowed by
ANVISA was 30 ppb up to 2002 and 20 ppb after that.
FDA has always recommended an AFB1 level less than 15
ppb. European Food Safety Authority (EFSA) allows only
0.1 ppb of AFB1 in some cases and there are specific rules
about food for child nutrition [36]. Moreover, residual
effects of exposition to higher aflatoxin levels before 2002
will probably yield high rates of AFB-related HCC in Bra-
zil for the next few decades.
Our data might suggest that 249Ser is related not only to
poorly differentiated HCC but also to also larger tumors.
It was showed that mutations among TP53 are associated
with poor differentiation level [37,38]. However, in both
studies there was a low 249Ser frequency and the poor dif-
ferentiation was associated only to TP53 mutation and
not to 249Ser itself. Moreover, neither of those studies
found association between TP53 mutation and tumor
size. Age and vascular invasion did not present correlation
with the specific mutation. Despite not presenting statisti-
cal relationship with 249Ser, the mutation had a tendency
of being more frequent in cirrhotic liver. The same can be
said about gender: The mutation was observed slightly
more frequently in males rather in female ones (p =
0.076).
The fact that the mutation was more frequent among
larger and less differentiated tumors could suggest that
249Ser is a late event on liver carcinogenesis, which may
sound, be against the hypothesis that AFB1 is a causal
agent of HCC. However, there are studies that describe the
selective advantages that a liver cell carrying this mutation
may have. Among them it could be pointed: enhancement
of cell growth [39], inhibition of wild-type p53 mediated
apoptosis [40] and finally p53 249ser has great efficiency
in suppressing wild-type p53 activity [41].
PCR-amplified products with mutant-specific primer for iden- tification of mutant TP-53 allele (lower 155 bp band) Figure 2
PCR-amplified products with mutant-specific primer 
for identification of mutant TP-53 allele (lower 155 
bp band). Lane 15 is a wild type control.
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Table 2: Mutation distribution according to Edmondson & 
Steiner histological grade
Histological Grade
12 34 T o t a l
Wild-Type 249 12 32 63 53
249Ser 07 8621
Total 1 30 3 9 74
p = 0.054
Table 3: Size difference between tumors according to 249Ser 
mutation
Codon 249 Samples Mean Size (cm)
Wild-Type 249 49* 5.5 ± 4.9
249Ser 19* 9.4 ± 7.4
p = 0.015
* Size information available for 68 samples
Table 4: Multivariable analysis of 249Ser associated factors
Odds Ratio 95% CI p
Grade 2.415 1.001 – 5.824 0.050
Male Gender 4.917 0.954 – 25.345 0.057
Tumor Size 1.102 1.001 – 1.214 0.047BMC Cancer 2009, 9:204 http://www.biomedcentral.com/1471-2407/9/204
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Interestingly, all HCC samples had low levels of mutant
p53-249 ser mutation as compared to wild-type p53 DNA.
Because larger and less differentiated tumors are less
homogeneous it is possible that only part of tumor dis-
played the p53-249ser mutation, following the suggesting
that 249ser is a late event on liver carcinogenesis. Altera-
tion in p53 may be important event in the transformation
of hepatocytes of regenerative nodules in a damaged
organ (the "field effect") to the malignant phenotype.
Also it is possible that part of non-tumor tissue with wild-
type p53DNA contributed for this situation, since it was
not performed micro dissection to separated only tumor
cells. Nevertheless, this situation did not preclude the
detection p53 249ser mutation in a significative number of
tumors, suggesting a role of aflatoxin in the carcinogenesis
of liver tumor in our country.
Statistical relationship between p53 249ser mutation and
HBV presence in the hepatocytes was not found. This,
however, may be due to the fact that only HBV DNA pres-
ence was analyzed and not its gene expression. Many stud-
ies describe that the pathway, which leads to the 249ser
mutation, is related with HBx expression however it was
not this project the aim. In this study HBV DNA presence
was not found being related to neither cirrhosis status nor
vascular invasion of the tumor.
Conclusion
In conclusion, the frequency of 249Ser found in this study
was 28%, which may suggest AFB1 exposure and indicat-
ing that this mutation is an important factor of HCC car-
cinogenesis in Brazil. HBV DNA presence did not show to
be a hazard factor to 249Ser development. However, it was
observed a relationship between poorly differentiated
HCC and tumor size to this specific mutation.
Even though the mutation frequency found in this study
was higher than those found in low HCC incidence areas,
it was still lower than countries with moderate AFB1 expo-
sure like Mexico.
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